[1] 马兵兵,王振华,管华.血清淀粉样蛋白A、超敏C反应蛋白联合检测对脓毒症患儿感染类型及病情严重程度的诊断价值[J].川北医学院学报,2021,36(3):344-346. DOI:10.3969/j.issn.1005-3697.2021.03.017.
[2] 李松,罗玲.新生儿败血症外周血中 PCT、SAA、CD64含量与炎症反应程度及脏器功能的相关性[J].海南医学院学报,2017,23(4):542-545. DOI:10.13210/j.cnki.jhmu. 20161205.002.
[3] 叶萃英,赵昕峰,洪书迟,等.血清淀粉样蛋白A、超敏C-反应蛋白、降钙素原在小儿脓毒血症中的诊断价值[J].中国卫生检验杂志,2019,29(14):1735-1737.
[4] 江载芳,申昆玲,沈颖. 禇福棠实用儿科学[M].8版.北京:人民卫生出版社,2012:15-16.
[5] Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine[J]. Chest, 1992, 101(6):1644-1655. DOI: 10.1378/chest.101.6.1644.
[6] 徐英,黄小平,陈丽,等.高密度脂蛋白胆固醇对HBV相关慢加急性肝衰竭严重程度及预后的预测价值[J].临床肝胆病杂志,2021,37(7):1632-1635. DOI:10.3969/j.issn.1001- 5256.2021.07.030.
[7] 刘开风.血清淀粉样蛋白A血管性血友病因子降钙素原及可溶性程序性死亡受体-1在重症监护室脓毒症患者预后和细菌类型的诊断价值[J].中国药物与临床,2022,22(4):340-344. DOI:10.11655/zgywylc2022.04.011.
[8] Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children[J]. Intensive Care Med, 2020, 46(Suppl 1):10-67. DOI: 10.1007/s00134-019-05878-6.
[9] 毛艳,杜亮,张冰斐,等.三酰甘油葡萄糖乘积指数、三酰甘油与高密度脂蛋白比值、稳态模型胰岛素抵抗指数、载脂蛋白B与载脂蛋白A1比值、高敏C反应蛋白与高尿酸血症的风险关系[J].临床肾脏病杂志,2022,22(3):200-208. DOI:10.3969/j.issn.1671-2390.2022.03.005.
[10] 纪小奇,陈婷,陈城,等.血清CysC、SAA联合APACHEⅡ评分对脓毒症合并急性肾损伤患者预后的评估价值[J].中华保健医学杂志,2022,24(2):125-127. DOI:10.3969/j.issn.1674-3245.2022.02.013.
[11] Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association[J]. Circulation, 2018, 138(1):e1-e34. DOI: 10.1161/CIR.0000000000000580.
[12] 戴晓勇,陈永珍,华玮,等.血清淀粉样蛋白A,C反应蛋白和降钙素原在脓毒性休克中的应用价值与相关性分析[J].现代检验医学杂志,2019,34(1):47-50. DOI:10.3969/j.issn.1671-7414.2019.01.012.
[13] 张涛,陈伟.稳定型冠心病患者血清低密度脂蛋白胆固醇和载脂蛋白B浓度与SYNTAX评分的关系[J].岭南心血管病杂志,2020,26(2):148-151,166. DOI:10.3969/j.issn.1007- 9688.2020.02.05.
[14] Velissaris D, Pierrakos C, Karamouzos V, et al. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review[J]. Acta Clin Belg, 2021, 76(1):79-84. DOI: 10.1080/17843286.2019. 1653519.
[15] 李国楠,张国强,张洪波,等.血清淀粉样蛋白A评估脓毒血症严重程度和预后的临床研究[J].中日友好医院学报,2021,35(3):143-145,161. DOI:10.3969/j.issn.1001-0025. 2021.03.004.
[16] 周曼丽,黄玉焕,吴靖,等.败血症患儿NLR、HMGB1及PCT表达与预后的关系[J].四川生理科学杂志,2022,44(3):475-477.
[17] Suzuki K, Terakawa T, Furukawa J, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab[J]. Int J Clin Oncol, 2020, 25(1):135-144. DOI: 10.1007/s10147-019-01528-5.
[18] 朱先华.血清miRNA-10a与IL-35水平对脓毒症诱导急性肾损伤患者预后评估价值[J].浙江中西医结合杂志,2019,29(6):451-456. DOI:10.3969/j.issn.1005-4561.2019. 06.007.
[19] 冯长福,周森,邢柏.可溶性CD73联合SOFA评分对脓毒症相关急性肾损伤患者28 d死亡风险的预测价值[J].中国急救医学,2022,42(1):13-18. DOI:10.3969/j.issn.1002-1949. 2022.01.004.
[20] 黄珊华,谢石坤,陈月娥,等.早产儿晚发型败血症高危因素分析及病原分布[J].广州医药,2019,50(1):100-102. DOI:10.3969/j.issn.1000-8535.2019.01.026.
[21] 米俊,周荣赛.血清肝素结合蛋白水平联合人院24h乳酸清除率对肺炎并发脓毒症患者预后的评估价值研究[J].临床急诊杂志,2020,21(1):91-95. DOI:10.13201/j.issn.1009- 5918.2020.01.016.
|